Viatris reported second-quarter revenue of $3.8 billion, up 3.5% operationally, and raised its full-year 2026 guidance across all key metrics. Adjusted EBITDA rose 8% operationally to $1.2 billion, and adjusted EPS grew 9% to $0.69, driven by 16% operational growth in Greater China and strength in North American complex generics. The company now expects 2026 revenue of $14.55 billion to $14.95 billion, adjusted EBITDA of $4.3 billion to $4.5 billion, and adjusted EPS of $2.45 to $2.59, with midpoints raised for all three. Viatris also announced FDA approval of its Gwyn Lo contraceptive patch, a $30 million upfront deal to sell Tyrvaya rights to Harrow, and completion of its Biocon stake sale for $380 million, while warning that Nashik facility disruptions could cut second-half revenue by $100 million to $150 million.
Viatris IncViatris raises 2026 guidance and reports strong Q2 results, including revenue and EPS growth.
Harrow Health IncViatris sells Tyrvaya rights to Harrow for $30 million upfront, a deal that adds to Harrow's portfolio.
